Literature DB >> 12163211

Cancer cachexia.

Kenneth C H Fearon1, Alastair G W Moses.   

Abstract

Cancer cachexia is a complex, multifactorial syndrome that results from a reduction in food intake, a variety of metabolic abnormalities (including hypermetabolism) or more often a combination of the two. Multiple mediator pathways including pro-inflammatory cytokines, neuroendocrine hormones and tumour-specific factors are involved. Therapy requires a multi-model approach that addresses both reduced food intake and metabolic change. Combination treatments such as nutritional support plus metabolic/inflammation modulation promise improved functional capacity and quality of life.

Entities:  

Mesh:

Year:  2002        PMID: 12163211     DOI: 10.1016/s0167-5273(02)00235-8

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  35 in total

Review 1.  Inflammation fuels tumor progress and metastasis.

Authors:  Jingyi Liu; Pengnian Charles Lin; Binhua P Zhou
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.

Authors:  Scott Shadfar; Marion E Couch; Kibwei A McKinney; Lisa J Weinstein; Xiaoying Yin; Jessica E Rodríguez; Denis C Guttridge; Monte Willis
Journal:  Nutr Cancer       Date:  2011-06-09       Impact factor: 2.900

Review 3.  Cancer cachexia: its correlations and causes.

Authors:  Harry Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

4.  Food insecurity among cancer patients in kentucky: a pilot study.

Authors:  Leigh Ann Simmons; Susan C Modesitt; Amanda C Brody; Allison B Leggin
Journal:  J Oncol Pract       Date:  2006-11       Impact factor: 3.840

5.  Animal models of anorexia and cachexia.

Authors:  Mark Daniel Deboer
Journal:  Expert Opin Drug Discov       Date:  2009-11-01       Impact factor: 6.098

6.  Adipose tissue pathways involved in weight loss of cancer cachexia.

Authors:  I Dahlman; N Mejhert; K Linder; T Agustsson; D M Mutch; A Kulyte; B Isaksson; J Permert; N Petrovic; J Nedergaard; E Sjölin; D Brodin; K Clement; K Dahlman-Wright; M Rydén; P Arner
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

7.  Body weight and fat-free mass changes in a cohort of patients receiving chemotherapy.

Authors:  Denise Halpern-Silveira; Lulie Rosane O Susin; Lúcia R Borges; Silvana I Paiva; Maria Cecília F Assunção; Maria Cristina Gonzalez
Journal:  Support Care Cancer       Date:  2009-07-21       Impact factor: 3.603

8.  CLA reduces inflammatory mediators from A427 human lung cancer cells and A427 conditioned medium promotes differentiation of C2C12 murine muscle cells.

Authors:  Manuela Oraldi; Marina Maggiora; Elena Paiuzzi; Rosa A Canuto; Giuliana Muzio
Journal:  Lipids       Date:  2012-11-07       Impact factor: 1.880

Review 9.  Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients.

Authors:  Todd T Brown; Danielle L Zelnik; Adrian S Dobs
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 10.  The role of inflammatory pathways in cancer-associated cachexia and radiation resistance.

Authors:  Aaron Laine; Puneeth Iyengar; Tej K Pandita
Journal:  Mol Cancer Res       Date:  2013-06-20       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.